Therapeutic Nanoparticles in Clinics and Under Clinical Evaluation

• Duncan R , GasparR. Nanomedicine(s) under the microscope. Mol. Pharm.8, 2101–2141 (2011).
   PubMed Web of Science ®Google Scholar
• Kreyling WG , Semmler-BehnkeM, ChaudhryQ. A complementary definition of nanomaterial. Nano Today5, 165–168 (2010).
   Web of Science ®Google Scholar
• Schütz CA , Juillerat-JeanneretL, SoltmannC, MuellerH. Toxicity data of therapeutic nanoparticles in patent documents. World Patent Inf. doi: 10.1016/j.wpi.2012.12.008 (2013) (Epub ahead of print).
   Google Scholar
• Junghanns JU , MüllerRH. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed.3, 295–309 (2008).
   PubMed Web of Science ®Google Scholar
• Heidel JD , DavisME. Clinical developments in nanotechnology for cancer therapy. Pharm. Res.28, 187–199 (2011).
   PubMed Web of Science ®Google Scholar
• Davis ME , ChenZG, ShinDM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov.7, 771–782 (2008).
   PubMed Web of Science ®Google Scholar
• Heath JR , DavisME. Nanotechnology and cancer. Annu. Rev. Med.59, 251–265 (2008).
   PubMed Web of Science ®Google Scholar
• Peer D , KarpJM, HongS, FarokhzadOC, MargalitR, LangerR. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2, 751–760 (2007).
   PubMed Web of Science ®Google Scholar
• Service RF . Materials and biology. Nanotechnology takes aim at cancer. Science310, 1132–1134 (2005).
   PubMed Web of Science ®Google Scholar
• Slingerland M , GuchelaarHJ, GelderblomH. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today17, 160–166 (2012).
   PubMed Web of Science ®Google Scholar
• DiMasi JA , FeldmanL, SecklerA, WilsonA. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther.87, 272–277 (2010).
   PubMed Web of Science ®Google Scholar
• Diego L , AtayeeR, HelmonsP, HsiaoG, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin. Investig. Drugs20, 1047–1056 (2011).
   PubMed Web of Science ®Google Scholar
• Hu X , MillerL, RichmanSet al. A novel PEGylated interferon β-1a for multiple sclerosis: safety, pharmacology, and biology. J. Clin. Pharmacol. 52, 798–808 (2012).
   PubMed Web of Science ®Google Scholar
• Egger S , LehmannRP, HeightMJ, LoessnerMJ, SchupplerM. Antimicrobial properties of a novel silver-silica nanocomposite material. Appl. Environ. Microbiol.75, 2973–2976 (2009).
   PubMed Web of Science ®Google Scholar
• Arrowsmith J . Trial watch: Phase II failures: 2008–2010. Nat. Rev. Drug Discov.10, 328–329 (2011).
   PubMed Web of Science ®Google Scholar
• Arrowsmith J . Trial watch: Phase III and submission failures: 2007–2010. Nat. Rev. Drug Discov.10, 87 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang JA , XuanT, ParmarMet al. Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 270, 93–107 (2004).
   PubMed Web of Science ®Google Scholar
• Kelkar SS , ReinekeTM. Theranostics: combining imaging and therapy. Bioconjug. Chem.22, 1879–1903 (2011).
   PubMed Web of Science ®Google Scholar
• Cheng Z , Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science338, 903–910 (2012).
   PubMed Web of Science ®Google Scholar
• Vicent MJ , RingsdorfH, DuncanR. Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev.61, 1117–1120 (2009).
   PubMed Web of Science ®Google Scholar
• Pasut G , VeroneseFM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev.61, 1177–1188 (2009).
   PubMed Web of Science ®Google Scholar
• Wang AZ , LangerR, FarokhzadOC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med.63, 185–198 (2012).
   PubMed Web of Science ®Google Scholar
• Karussis D , TeitelbaumD, SicsicC, BrennerT. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J. Neuroimmunol.220, 125–130 (2010).
   PubMed Web of Science ®Google Scholar
• Jung CW . Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn. Reson. Imaging13, 675–691 (1995).
   PubMed Web of Science ®Google Scholar
• Zamboni WC . Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist13, 248–260 (2008).
   PubMed Web of Science ®Google Scholar
• Herzog C , HartmannK, KünziVet al. Eleven years of Inflexal V – a virosomal adjuvanted influenza vaccine. Vaccine 27, 4381–4387 (2009).
   PubMed Web of Science ®Google Scholar
• Glantz MJ , LaFolletteS, JaeckleKAet al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 17, 3110–3116 (1999).
   PubMed Web of Science ®Google Scholar
• Duncan R . Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer6, 688–701 (2006).
   PubMed Web of Science ®Google Scholar
• Goldfine AB , FonsecaVA, JonesMR, WangAC, FordDM, TruittKE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm. Metab. Res.42, 23–30 (2010).
   PubMed Web of Science ®Google Scholar
• Wang YX , HussainSM, KrestinGP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur. Radiol.11, 2319–2331 (2001).
   PubMed Web of Science ®Google Scholar
• Simon JA ; ESTRASORB Study Group. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause13, 222–231 (2006).
   PubMed Web of Science ®Google Scholar
• Howell SB . Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam technology. Cancer J.7, 219–227 (2001).
   PubMed Web of Science ®Google Scholar
• Curran MP , McCormackPL. Methoxy polyethylene glycol-epoetin β: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs68, 1139–1156 (2008).
   PubMed Web of Science ®Google Scholar
• Mease PJ . Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology50, 261–270 (2011).
   PubMed Web of Science ®Google Scholar
• Singh A , PatelT, HertelJ, BernardoM, KauszA, BrennerL. Safety of ferumoxytol in patients with anemia and CKD. Am. J. Kidney Dis.52, 907–915 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson PM , TomarasM, McConnellK. Mifamurtide in osteosarcoma – a practical review. Drugs Today46, 327–337 (2010).
   PubMed Web of Science ®Google Scholar
• Bovier PA . Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines7, 1141–1150 (2008).
   PubMed Web of Science ®Google Scholar
• Gommans GM , GommansE, van der Zant FM, Teule GJ, van der Schors TG, de Waard JW. 99mTc nanocoll: a radiopharmaceutical for sentinel node localisation in breast cancer – in vitro and in vivo results. Appl. Radiat. Isot.67, 1550–1558 (2009).
   PubMed Web of Science ®Google Scholar
• Rodriguez MA , PytlikR, KozakTet al. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal Phase 2 study. Cancer 115, 3475–3482 (2009).
   PubMed Web of Science ®Google Scholar
• Shen LJ , ShenWC. Drug evaluation: ADI-PEG-20 – a PEGylated arginine deiminase for arginine-auxotrophic cancers. Curr. Opin. Mol. Ther.8, 240–248 (2006).
   PubMed Web of Science ®Google Scholar
• Vogel CL , WojtukiewiczMZ, CarrollRRet al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled Phase III study. J. Clin. Oncol. 23, 1178–1184 (2005).
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP , BoulikasT. Lipoplatin formulation review article. J. Drug Deliv.2012, 581363 (2012).
   PubMedGoogle Scholar
• Herborn CU , BarkhausenJ, PaetschIet al. Coronary arteries: contrast-enhanced MR imaging with SH L 643A – experience in 12 volunteers. Radiology 229, 217–223 (2003).
   PubMed Web of Science ®Google Scholar
• Wood BJ , PoonRT, LocklinJKet al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J. Vasc. Interv. Radiol. 23, 248–255 (2012).
   PubMed Web of Science ®Google Scholar
• Mathew J , PerezEA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr. Opin. Oncol.23, 594–600 (2011).
   PubMed Web of Science ®Google Scholar
• Desai NP . Nab Technology: Nab Technology: A Drug Delivery Platform Utilising Endothelial’ gp60 Receptor-based Transport and Tumour-derived SPARC for Targeting. PharmaVentures Ltd, Oxford, UK 37–41 (2007–2008).
   Google Scholar
• Rademaker-Lakhai JM , TerretC, HowellSBet al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res. 10, 3386–3395 (2004).
   PubMed Web of Science ®Google Scholar
• Keefe AD , PaiS, EllingtonA. Aptamers as therapeutics. Nat. Rev. Drug Discov.9, 537–550 (2010).
   PubMed Web of Science ®Google Scholar
• Stern ST , HallJB, YuLLet al. Translational considerations for cancer nanomedicine. J. Control. Release 146, 164–174 (2010).
   PubMed Web of Science ®Google Scholar
• Venkatraman SS , MaLL, NatarajanJV, ChattopadhyayS. Polymer- and liposome-based nanoparticles in targeted drug delivery. Front. Biosci. (Schol. Ed.)2, 801–814 (2010).
   PubMedGoogle Scholar
• Svenson S , WolfgangM, HwangJ, RyanJ, EliasofS. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J. Control. Release153, 49–55 (2011).
   PubMed Web of Science ®Google Scholar
• Shiose Y , OchiY, KugaH, YamashitaF, HashidaM. Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors. Biol. Pharm. Bull.30, 2365–2370 (2007).
   PubMed Web of Science ®Google Scholar
• Seymour LW , FerryDR, KerrDJet al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 34, 1629–1636 (2009).
   PubMed Web of Science ®Google Scholar
• Naumovski L , JunutulaJR. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr. Opin. Mol. Ther.12, 248–257 (2010).
   PubMed Web of Science ®Google Scholar
• Apostolidou E , SwordsR, AlvaradoY, GilesFJ. Treatment of acute lymphoblastic leukaemia: a new era. Drugs67, 2153–2171 (2007).
   PubMed Web of Science ®Google Scholar
• Maier-Hauff K , UlrichF, NestlerDet al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103, 317–324 (2011).
   PubMed Web of Science ®Google Scholar
• Plummer R , WilsonRH, CalvertHet al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104, 593–598 (2011).
   PubMed Web of Science ®Google Scholar
• Hamaguchi T , DoiT, Eguchi-NakajimaTet al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res. 16, 5058–5066 (2010).
   PubMed Web of Science ®Google Scholar
• Kato K , ChinK, YoshikawaTet al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 30, 1621–1627 (2012).
   PubMed Web of Science ®Google Scholar
• Duffaud F , BornerM, CholletP. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur. J. Cancer40, 2748–2752 (2004).
   PubMed Web of Science ®Google Scholar
• Ricart AD , BerlinJD, PapadopoulosKPet al. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin. Cancer Res. 14, 7947–7955 (2008).
   PubMed Web of Science ®Google Scholar
• Scott LC , YaoJC, BensonAB 3rd et al. A Phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother. Pharmacol.63, 363–370 (2009).
   PubMed Web of Science ®Google Scholar
• Mueller C , Al-BatranS, JaegerEet al.: A Phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients with advanced refractory solid tumors. Program and Abstracts of the 44th American Society of Clinical Oncology Annual MeetingChicago, IL, USA, 30 May–3 June 2008 (Abstract 2533).
   Google Scholar
• Zhao H , RubioB, SapraPet al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug. Chem. 19, 849–859 (2008).
   PubMed Web of Science ®Google Scholar
• Nowotnik DP , CvitkovicE. ProLindac (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv. Drug. Deliv. Rev.61, 1214–1219 (2009).
   PubMed Web of Science ®Google Scholar
• Wittgen BP , KunstPW, van der Born K et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin. Cancer Res.13, 2414–2421 (2007).
   PubMed Web of Science ®Google Scholar
• Valle JW , ArmstrongA, NewmanCet al. A Phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 29, 1029–1037 (2011).
   PubMed Web of Science ®Google Scholar
• White SC , LoriganP, MargisonGPet al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br. J. Cancer 95, 822–828 (2006).
   PubMed Web of Science ®Google Scholar
• Constantinides PP , ChaubalMV, ShorrR. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev.60, 757–767 (2008).
   PubMed Web of Science ®Google Scholar
• Aleku M , SchulzP, KeilOet al. Atu027, a liposomal siRNA formulation targeting PKN3, inhibits cancer progression. Cancer Res. 68, 9788–9798 (2008).
   PubMed Web of Science ®Google Scholar
• Bomalaski JS , HoltsbergFW, EnsorCM, ClarkMA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J. Rheumatol.29, 1942–1949 (2002).
   PubMed Web of Science ®Google Scholar
• Sanna V , SechiM. Nanoparticle therapeutics for prostate cancer treatment. Maturitas73, 27–32 (2012).
   PubMed Web of Science ®Google Scholar
• Eifler AC , ThaxtonCS. Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol. Biol.726, 325–338 (2011).
   PubMedGoogle Scholar
• Danhauser-Riedl S , HausmannE, SchickHDet al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs 11, 187–195 (1993).
   PubMed Web of Science ®Google Scholar
• Dritschilo A , HuangCH, RudinCMet al. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 12, 1251–1259 (2006).
   PubMed Web of Science ®Google Scholar
• de Jonge MJ , SlingerlandM, LoosWJet al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur. J. Cancer 46, 3016–3021 (2010).
   PubMed Web of Science ®Google Scholar
• Noble CO , KrauzeMT, DrummondDCet al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 66, 2801–2806 (2006).
   PubMed Web of Science ®Google Scholar
• Meerum Terwogt JM , ten Bokkel Huinink WW, Schellens JH et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs12, 315–323 (2001).
   PubMed Web of Science ®Google Scholar
• Bremerich J , BilecenD, ReimerP. MR angiography with blood pool contrast agents. Eur. Radiol.17, 3017–3024 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh MD , HannaSK, SenJMet al. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin. Cancer Res. 18, 2591–2602 (2012).
   PubMed Web of Science ®Google Scholar
• Toudjarska I , CaiZ, RacieTet al.: RNAi-mediated inhibition of activated protein C – A new approach for hemophilia treatment. Program and Abstracts of the 53rd American Society of Hematology Annual Meeting. San Diego, CA, USA, 10–13 December 2011 (Abstract 1204).
   Google Scholar
• Akinc A , Chan-DanielsA, SehgalAet al.: Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. Program and Abstracts of the 53rd American Society of Hematology Annual Meeting. San Diego, CA, USA, 10–13 December 2011 (Abstract 688).
   Google Scholar
• Harada M , BobeI, SaitoHet al. Improved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300. Cancer Sci. 102, 192–199 (2011).
   PubMed Web of Science ®Google Scholar
• Nolte-Ernsting C , AdamG, BückerA, BergesS, Bj⊘rnerudA, GüntherRW. Abdominal MR angiography performed using blood pool contrast agents: comparison of a new superparamagnetic iron oxide nanoparticle and a linear gadolinium polymer. Am. J. Roentgenol.171, 107–113 (1998).
   PubMed Web of Science ®Google Scholar
• McCoy M . A transatlantic polymeric solution – CASE STUDY#1: helped by a German custom synthesis firm, a U.S. biotech start-up tackles kidney ailment with a specialty polymer. Chem. Eng. News85, 18–20 (2007).
   Google Scholar
• Jensen SS , AndresenTL, DavidsenJet al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol. Cancer Ther. 3, 1451–1458 (2004).
   PubMed Web of Science ®Google Scholar
• Morrow KJ Jr, Bawa R, Wei C. Recent advances in basic and clinical nanomedicine. Med. Clin. N. Am.91, 805–843 (2007).
   PubMed Web of Science ®Google Scholar
• Bhol KC , SchechterPJ. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig. Dis. Sci.52, 2732–2742 (2007).
   PubMed Web of Science ®Google Scholar
• Kabanov AV , AlakhovVY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst.19, 1–72 (2002).
   PubMed Web of Science ®Google Scholar
• Geisbert TW , LeeAC, RobbinsMet al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896–1905 (2010).
   PubMed Web of Science ®Google Scholar

Websites

• European Comission. Nanomaterials. http://ec.europa.eu/environment/chemicals/nanotech/index.htm
   Google Scholar
• US FDA. www.fda.gov
   Google Scholar
• NIH clinical trials register. www.clinicaltrials.gov
   Google Scholar
• Swiss Agency for Therapeutic Products (Swissmedic). www.swissmedic.ch
   Google Scholar
• EMA. www.ema.europa.eu
   Google Scholar
• EU. www.eurunion.org
   Google Scholar